Artelo Biosciences (NASDAQ:ARTL) Given Hold Rating at Maxim Group

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “hold” rating reaffirmed by stock analysts at Maxim Group in a research note issued to investors on Wednesday,Benzinga reports.

Several other brokerages have also recently issued reports on ARTL. Wall Street Zen cut shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, August 9th. D. Boral Capital reaffirmed a “hold” rating on shares of Artelo Biosciences in a research note on Monday, September 8th. D Boral Capital cut Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artelo Biosciences in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Artelo Biosciences Trading Down 2.6%

ARTL stock traded down $0.05 during midday trading on Wednesday, hitting $1.84. 7,618 shares of the company’s stock were exchanged, compared to its average volume of 275,690. The business has a 50-day simple moving average of $3.94 and a two-hundred day simple moving average of $7.41. Artelo Biosciences has a 1-year low of $1.66 and a 1-year high of $28.60. The stock has a market capitalization of $1.29 million, a PE ratio of -0.09 and a beta of 1.23.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($3.15). As a group, research analysts expect that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.